Skip to main content

Table 1 Clinical data concerning primary neuroblastomas used in this study

From: Verification of genes differentially expressed in neuroblastoma tumours: a study of potential tumour suppressor genes

Group

Case

INSS

INRGSS

Age

Outcome

Ploidy

MNA

1p del

11q del

17q gain

OS

Ver. Group

Seq

CNA

F

23R4

1

L

       

105

1

x

 
 

14E6MA

1

L

       

201

ni

  
 

18E8

1

L

      

WCG

169

1

x

 
 

31R8

1

L

A

      

73

1

  
 

35R8

1

L

I

      

50

1

  
 

26R9

1

L

       

91

2

  
 

16E1

1

L

I

 

2n

    

190

2

  
 

37R6

1

L

       

37

2

  
 

20R9

2

L

  

2n

  

nd

nd

113

1

x

 
 

33R7

2

L

     

nd

nd

62

1

x

 
 

25R9

2

L

A

 

2n

    

95

2

  
 

10R6

2

L

  

2n

nd

nd

nd

nd

160

2

  
 

13E8

2

L

A

      

202

2

  
 

12E8MA

3

L

  

2n

   

WCG

209

0

  
 

15E3MA

3

L

   

Gain

UB

 

WCG

195

0

  
 

21R6

4S

MS

  

2n

    

111

2

  

UF

19R6

3

L

 

DOD

2n

y

y

 

y

8

1

x

 
 

16R4MA

3

L

A

  

y

  

y

131

0

x

 
 

9R9

3

M

A

DOD

2n

 

y

y

y

21

1

x

x

 

10R8

3

L

A

DOD

2n

 

y

y

y

59

2

 

x

 

10R2MA

4

M

I

DOD

2n

y

y

 

y

12

0

  
 

15R3MA

4

M

A

DOD

2n

 

y

nd

y

9

0

x

 
 

12E6

4

M

A

DOD

2n

y

 

nd

(y)

9

1

  
 

13R0

4

M

A

DOD

2n

y

y

 

y

10

1

  
 

26R8

4

M

I

DOD

2n

y

y

nd

nd

18

1

  
 

29R2

4

M

I

 

2n

y

y

nd

nd

85

1

  
 

11E1

4

M

A

 

2n

  

y

y

218

2

 

x

 

26R0

4

M

A

 

2n

Gain

y

y

y

93

2

  
 

34R0

4

M

A

DOD

2n

   

y

11

2

 

x

 

39R1

?

M

I

 

2n

y

y

 

y

29

2

 

x

 

12E3

4

M

I

DOD

2n

y

y

 

y

4

2

 

x

  1. Column 1: Group, F = Favourable, UF = unfavourable; column 2: Case ID, MA = Cases used in the Microarray study; column 3: Clinical stage according to International Neuroblastoma Staging System (INSS) [2]; column 4: Clinical stage according to International Neuroblastoma Risk Group Staging System (INRGSS) [23], L = locoregional tumors, M = metastatic tumors, MS = metastases are confined to the skin, liver, and/or bone marrow in children younger than 18 months of age.; column 5: Age = Age at diagnosis, B = Below 12 months, I = Intermediate, i.e. 12–24 months, A = Above 24 months; column 6: Outcome: DOD = Dead of disease, nd = not determined; column 7: Ploidy: 2n = Diploidy; column 8: MNA = MYCN amplification, y = MNA, gain = MYCN< 4 times the ploidy; column 9: 1p del = 1p deletion, y = 1p del, UB = unbalanced; column 10: 11q del = 11q deletion, y = 11q del; column 11: y = 17q gain, WCG = whole chromosome gain, (y) = uncertain results; column 12: Overall survival (OS) in months; column 13: Verification groups (Ver.Group) with QPCR, 0 = Replicate group, 1 = Verification group 1, 2 = Verification group 2, ni = not included; column 14: Seq = Cases used for DNA Sequencing or Bisulphite Sequencing PCR (BSP) of POU4F2; column 15: CNA = Cases used for Copy Number Aberration analysis of CNTNAP2.
Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us